dr. bekaii-saab on the response rate of pembrolizumab in msi-h crc
Published 6 years ago • 302 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
9:02
pembrolizumab in msi-h crc tumors
-
1:20
dr. saab on immunotherapy in msi-h gi malignancies
-
1:30
tanios bekaii-saab, md on msi-high as an mcrc response predictor to nivolumab (opdivo)
-
3:47
dr bekaii-saab on the future of treatment for patients with gi cancer
-
1:27
dr. grothey on fda approval of pembrolizumab in msi-high crc
-
9:54
progress report iv - sarolta beáta kávási
-
9:00
gene expression profile predicts response to pembrolizumab
-
4:41
actively living with colorectal cancer: stephen's immunotherapy story
-
1:35
dr. chu on the role of pembrolizumab in dmmr/msi-h mcrc
-
2:04
dr. bekaii saab on the role of immunotherapy in crc
-
1:49
dr. bekaii-saab on resistance to targeted therapy in crc
-
2:42
dr. bekaii-saab discusses an analysis of bevacizumab or cetuximab for crc
-
0:56
dr. bekaii-saab on tolerability of encorafenib, binimetinib, and cetuximab in braf crc
-
1:39
dr. bekaii-saab on microsatellite instability in colorectal cancer
-
1:33
dr. bekaii saab on the expansion of treatment options in colorectal cancer
-
2:06
dr. bekaii-saab on the impact of the beacon crc study in braf-mutated crc
-
1:24
dr. catenacci on study of margetuximab plus pembrolizumab in gastric:gej cancer
-
0:54
dr. diaz on response rates with pembrolizumab for crc
-
1:49
dr. bekaii-saab on immunotherapy in colorectal cancer
-
1:19
dr. bekaii-saab discusses an analysis of bevacizumab or cetuximab for crc
-
0:46
dr. bekaii saab on immunotherapeutic options in crc beyond pd-1/pd-l1
-
0:57
dr. bekaii-saab on the importance of the redos study in mcrc